Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

New Immunotherapy Target Identified

Immunotherapy is a type of cancer treatment that uses your own immune system to help fight cancer. Stimulating a patient’s own immune system can be highly effective at recognizing and destroying cancer cells. Programmed death-ligand 1 (PD-L1) is a transmembrane protein that can suppress the immune response by inhibiting the proliferation of T cells via apoptosis. It also plays an important role in arresting cell-cycle progression. Normally, the immune system will detect foreign antigens and trigger the proliferation of the immune response including T cells. The binding of programmed cell death-1 (PD-1) to PD-L1 reduces the proliferation of the T cells. PD1/PD-L1 interaction ensures that activation of the immune system occurs at the appropriate time and to minimize the possibility of chronic autoimmune inflammation.

Unfortunately, upregulation of PD-L1 may allow cancers to evade the immune response. Many immune-oncology therapies use PD-L1 inhibitors with great success. PD-1 can trick your immune system into overlooking cancer cells as normal cells. Recently, a new report identified another protein, CMTM6, which stabilizes PD-L1 and increases the ability of cancer cells to avoid being destroyed by inhibiting the immune response. CMTM6 was identified using a genome-wide CRISPR–Cas9 screen. CMTM6 co-localizes with PD-L1 at the plasma membrane and in endosomes, where it prevents PD-L1 from being degraded. Interestingly, interfering with CMTM6 expression impairs PD-L1 protein expression. Therefore, this makes CMTM6 an attractive therapeutic target for cancer and immunologic diseases.

For more information: https://www.ncbi.nlm.nih.gov/labs/articles/28813417/

Enzo provides a wide variety of products for your Cancer and Immunology research needs. We create innovative assays and reagents in the fields of epigenetics, autophagy, and Wnt research. These novel tools, and a broad portfolio of products established for decades in peer-reviewed literature, will help support cancer discovery into the next decade, and beyond. We offer our SCREEN-WELL® Cancer Library, a collection of 275 compounds that can be used for screening and assay development. Our portfolio also includes kits, antibodies and proteins including PD-L1, PD-1 and MEGACD40L® to aid your research.

Never miss a new TechNote!

Receive our TechNotes as soon as they are published.


 
comments powered by Disqus

follow Us!

 

Related Products

PD-1 (human), (recombinant) 

Produced in HEK cells. Extracellular domain of PD-1 (aa 25-167) containing a 5’-His-tag, V5 epitope tag spacer, and a FLAG-tag., ≥90% (SDS-PAGE) | Print as PDF
 
ENZ-PRT190-0050 50 µg 301.00 USD
 

PD-L1 (human), (recombinant) 

Produced in HEK cells. Human PD-L1 (aa 19-239) is fused at the N-terminus to a His-tag and FLAG®-tag., ≥90% (SDS-PAGE) | Print as PDF
 
ENZ-PRT223-0100 100 µg 350.00 USD
Do you need bulk/larger quantities?
 

SCREEN-WELL® Cancer Library 

Essential standards for cancer inhibitor screening
HTS | Print as PDF
 
ENZ-LIB102-0100 1 Library 100 µl/well Inquire for pricing
Do you need bulk/larger quantities?
 

CD40L, soluble (human) (recombinant) set 

Ligand plus enhancer for improved stability and enhanced immune activation.
Produced in E. coli. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to a linker peptide (6 aa) and a FLAG®-tag., ≥95% (SDS-PAGE)., FUNC | Print as PDF
 
ALX-850-064-KI01 1 Set 505.00 USD
Do you need bulk/larger quantities?
 

CD40L monoclonal antibody (5F3) 

Flow Cytometry | Print as PDF
 
ADI-CSA-187-E 100 µg 313.00 USD
Do you need bulk/larger quantities?
 

CD40L (human) monoclonal antibody (blocking) (MK13A4) 

Flow Cytometry, FUNC | Print as PDF
 
ALX-805-037-C100 100 µg Purified 291.00 USD
Do you need bulk/larger quantities?
 

Fc (human):CD40L (soluble) (human), (recombinant) 

Produced in HEK 293 cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to the Fc portion of human IgG1 and a linker peptide (20 aa)., ≥90% (SDS-PAGE), ELISA, FUNC | Print as PDF
 
ALX-522-076-C010 10 µg 425.00 USD
Do you need bulk/larger quantities?
 

CD40 polyclonal antibody 

WB | Print as PDF
 
ADI-CSS-180-D 50 µg 161.00 USD
 
ADI-CSS-180-F 200 µg 399.00 USD
Do you need bulk/larger quantities?
 

CD40 (human):Fc (human), (recombinant) 

Produced in HEK 293 cells. The cysteine-rich region (aa 21-193) of human CD40 is fused to the Fc portion of human IgG1., ≥95% (SDS-PAGE), ELISA | Print as PDF
 
ALX-522-016-C050 50 µg 370.00 USD
Do you need bulk/larger quantities?
 

CD40L, soluble (human) ELISA kit (high sensitivity) 

ELISA | Print as PDF
 
ALX-850-311-KI01 96 wells 689.00 USD
Do you need bulk/larger quantities?
 

CD40 (human):COMP (human), (recombinant) 

First non-antibody blocker of CD40L signalling
Produced in HEK 293 cells. The extracellular domain of human CD40 (aa 1-193) is fused to a FLAG®-tag at the N-terminus and to human cartilage oligomeric matrix protein (COMP, aa 32-80) at the C-terminus., ≥90% (SDS-PAGE) | Print as PDF
 
ALX-522-064-C010 10 µg 425.00 USD
Do you need bulk/larger quantities?
 

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,